Humalog® Mix50/50(tm) as a Treatment for Gestational Diabetes

• Status: Completed
• Trial end date: 2010-10-01
• Target enrollment: 0
• Participant gender: Female

Summary

Humalog® Mix50/50TM administered as 3 injections daily is equivalent to Humalog® plus Humulin N® insulin administered as 6 separate injections daily in terms of glucose control, but may have some advantages due to increased ease of use.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sansum Diabetes Research Institute; William Sansum Diabetes Center
• Collaborator: Eli Lilly and Company
• Treatments: Biphasic Insulins; Insulin; Insulin Lispro; Insulin, Globin Zinc; Insulin, Isophane; Insulin, Long-Acting; Isophane insulin, insulin lispro drug combination 50:50

Criteria

Inclusion Criteria:

• Pregnant and at least 13 weeks gestation

• Diagnosed with gestational diabetes mellitus

• Failed diet therapy

Exclusion Criteria:

• <18 years old or over 45 years old

• urine dipstick >2+ protein

• blood pressure >140/80 mmHg

• hematocrit <30%

• refusal to take insulin

• inability to understand instructions or to consent to participate.